Assenagon Asset Management S.A. Has $196.02 Million Stock Holdings in Roivant Sciences Ltd. $ROIV

Assenagon Asset Management S.A. boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,076,488 shares of the company’s stock after purchasing an additional 139,376 shares during the period. Assenagon Asset Management S.A.’s holdings in Roivant Sciences were worth $196,019,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP grew its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the 4th quarter valued at $47,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after acquiring an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC grew its position in Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after acquiring an additional 1,704 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Matthew Gline sold 289,774 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the sale, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 703,312 shares of company stock worth $20,805,883 over the last ninety days. 10.80% of the stock is owned by insiders.

Roivant Sciences Stock Up 5.6%

NASDAQ ROIV opened at $34.01 on Thursday. The company has a market capitalization of $24.46 billion, a price-to-earnings ratio of -56.68 and a beta of 1.13. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $34.51. The stock has a fifty day simple moving average of $29.47 and a 200 day simple moving average of $26.63.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same period in the previous year, the business earned ($0.29) EPS. Research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the subject of a number of recent research reports. Sanford C. Bernstein assumed coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price for the company. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Guggenheim raised their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.